Dexmedetomidine: A Review of Its Use for Sedation in the Intensive Care Setting
- 2.5k Downloads
Dexmedetomidine (Dexdor®) is a highly selective α2-adrenoceptor agonist. It has sedative, analgesic and opioid-sparing effects and is suitable for short- and longer-term sedation in an intensive care setting. In the randomized, double-blind, multicentre MIDEX and PRODEX trials, longer-term sedation with dexmedetomidine was noninferior to midazolam and propofol in terms of time spent at the target sedation range, as well as being associated with a shorter time to extubation than midazolam or propofol, and a shorter duration of mechanical ventilation than midazolam. Patients receiving dexmedetomidine were also easier to rouse, more co-operative and better able to communicate than patients receiving midazolam or propofol. Dexmedetomidine had beneficial effects on delirium in some randomized, controlled trials (e.g. patients receiving dexmedetomidine were less likely to experience delirium than patients receiving midazolam, propofol or remifentanil and had more delirium- and coma-free days than patients receiving lorazepam). Intravenous dexmedetomidine had an acceptable tolerability profile; hypotension, hypertension and bradycardia were the most commonly reported adverse reactions. In conclusion, dexmedetomidine is an important option for sedation in the intensive care setting.
KeywordsMidazolam Remifentanil Intensive Care Unit Stay Dexmedetomidine Intensive Care Patient
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit. Gillian Keating is a salaried employee of Adis/Springer.
- 4.European Medicines Agency. Dexdor (dexmedetomidine): EU summary of product characteristics. 2015. http://www.ema.europa.eu/. Accessed 4 May 2015.
- 7.European Medicines Agency. Dexmedetomidine: assessment report. 2011. http://www.ema.europa.eu/. Accessed 4 May 2015.
- 29.Goodwin HE, Gill RS, Murakami PN, et al. Dexmedetomidine preserves attention/calculation when used for cooperative and short-term intensive care unit sedation. J Crit Care. 2013;28(6):1113e7–e10.Google Scholar